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BACKGROUND: Visual outcome is one of the main issues in the treatment of optic
pathway glioma in childhood. Although the prognostic factors of low vision have been
discussed extensively, no reliable indicators for visual loss exist. Therefore, we aimed
to define initial and evolving factors associated with long-term vision loss.
METHODS: We conducted a multicenter historical cohort study of children treated in
France with up-front BB-SFOP chemotherapy between 1990 and 2004. Visual acuity
performed at the long-term follow-up visit or within 6 months prior was analyzed.
Logistic regression analysis was used to estimate the effects of clinical and
radiological factors on long-term visual outcome.
FINDINGS: Of the 180 patients in the cohort, long-term visual acuity data were
available for 132 (73.3%) patients (median follow-up: 14.2 years; range: 6.1-25.6). At
the last follow-up, 61/132 patients (46.2%) had impaired vision, and 35 of these
patients (57.3%) were partially sighted or blind. Multivariate analysis showed that
factors associated with a worse prognosis for long-term visual acuity were an age at
diagnosis of < 1 year (OR 3.5 [95% CI: 1.1-11.2], p = 0.04), tumor extent (OR 4.7
[95% CI: 1.2-19.9], p = 0.03), intracranial hypertension requiring one or more surgical
procedures (OR 5.6 [95% CI: 1.8-18.4], p = 0.003), and the need for additional
treatment after initial BB-SFOP chemotherapy (OR 3.5 [95% CI: 1.1-11.9], p = 0.04).
NF1 status did not appear as a prognostic factor, but in non-NF1 patients, a decrease
in tumor volume with contrast enhancement after BB-SFOP chemotherapy was
directly associated with a better visual prognosis (OR 0.8 [95% CI: 0.8-0.9], p = 0.04).
INTERPRETATION: Our study confirms that a large proportion of children with optic
pathway glioma have poor long-term outcomes of visual acuity. These data suggest
new prognostic factors for visual acuity, but these results need to be confirmed
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